466 related articles for article (PubMed ID: 17510248)
1. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers.
Waldmeier F; Glaenzel U; Wirz B; Oberer L; Schmid D; Seiberling M; Valencia J; Riviere GJ; End P; Vaidyanathan S
Drug Metab Dispos; 2007 Aug; 35(8):1418-28. PubMed ID: 17510248
[TBL] [Abstract][Full Text] [Related]
2. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects.
Vaidyanathan S; Maboudian M; Warren V; Yeh CM; Dieterich HA; Howard D; Dole WP
Curr Med Res Opin; 2008 Aug; 24(8):2313-26. PubMed ID: 18786303
[TBL] [Abstract][Full Text] [Related]
3. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects.
Ayalasomayajula S; Tchaloyan S; Yeh CM; Bizot MN; Dieterich HA; Howard D; Dole WP
Curr Med Res Opin; 2008 Mar; 24(3):717-26. PubMed ID: 18234150
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment.
Vaidyanathan S; Warren V; Yeh C; Bizot MN; Dieterich HA; Dole WP
J Clin Pharmacol; 2007 Feb; 47(2):192-200. PubMed ID: 17244770
[TBL] [Abstract][Full Text] [Related]
5. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
Vaidyanathan S; Valencia J; Kemp C; Zhao C; Yeh CM; Bizot MN; Denouel J; Dieterich HA; Dole WP
Int J Clin Pract; 2006 Nov; 60(11):1343-56. PubMed ID: 17073832
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects.
Vaidyanathan S; Reynolds C; Yeh CM; Bizot MN; Dieterich HA; Howard D; Dole WP
J Clin Pharmacol; 2007 Apr; 47(4):453-60. PubMed ID: 17389554
[TBL] [Abstract][Full Text] [Related]
7. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
[TBL] [Abstract][Full Text] [Related]
8. Influence of body weight and gender on the pharmacokinetics, pharmacodynamics, and antihypertensive efficacy of aliskiren.
Jarugula V; Yeh CM; Howard D; Bush C; Keefe DL; Dole WP
J Clin Pharmacol; 2010 Dec; 50(12):1358-66. PubMed ID: 20150520
[TBL] [Abstract][Full Text] [Related]
9. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans.
Prakash C; Kamel A; Gummerus J; Wilner K
Drug Metab Dispos; 1997 Jul; 25(7):863-72. PubMed ID: 9224781
[TBL] [Abstract][Full Text] [Related]
10. Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans.
He H; Tran P; Yin H; Smith H; Batard Y; Wang L; Einolf H; Gu H; Mangold JB; Fischer V; Howard D
Drug Metab Dispos; 2009 Mar; 37(3):536-44. PubMed ID: 19074975
[TBL] [Abstract][Full Text] [Related]
11. Absorption, metabolism, and excretion of [(14)C]MK-0524, a prostaglandin D(2) receptor antagonist, in humans.
Karanam B; Madeira M; Bradley S; Wenning L; Desai R; Soli E; Schenk D; Jones A; Dean B; Doss G; Garrett G; Crumley T; Nirula A; Lai E
Drug Metab Dispos; 2007 Jul; 35(7):1196-202. PubMed ID: 17431030
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics and pharmacodynamics of aliskiren.
Vaidyanathan S; Jarugula V; Dieterich HA; Howard D; Dole WP
Clin Pharmacokinet; 2008; 47(8):515-31. PubMed ID: 18611061
[TBL] [Abstract][Full Text] [Related]
13. Metabolism and disposition of imatinib mesylate in healthy volunteers.
Gschwind HP; Pfaar U; Waldmeier F; Zollinger M; Sayer C; Zbinden P; Hayes M; Pokorny R; Seiberling M; Ben-Am M; Peng B; Gross G
Drug Metab Dispos; 2005 Oct; 33(10):1503-12. PubMed ID: 16006570
[TBL] [Abstract][Full Text] [Related]
14. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans.
Fisher ND; Jan Danser AH; Nussberger J; Dole WP; Hollenberg NK
Circulation; 2008 Jun; 117(25):3199-205. PubMed ID: 18559696
[TBL] [Abstract][Full Text] [Related]
15. Aliskiren: an oral direct renin inhibitor for the treatment of hypertension.
Sanoski CA
Pharmacotherapy; 2009 Feb; 29(2):193-212. PubMed ID: 19170589
[TBL] [Abstract][Full Text] [Related]
16. Disposition and metabolism of radiolabeled casopitant in humans.
Pellegatti M; Bordini E; Fizzotti P; Roberts A; Johnson BM
Drug Metab Dispos; 2009 Aug; 37(8):1635-45. PubMed ID: 19420128
[TBL] [Abstract][Full Text] [Related]
17. Pimecrolimus: absorption, distribution, metabolism, and excretion in healthy volunteers after a single oral dose and supplementary investigations in vitro.
Zollinger M; Waldmeier F; Hartmann S; Zenke G; Zimmerlin AG; Glaenzel U; Baldeck JP; Schweitzer A; Berthier S; Moenius T; Grassberger MA
Drug Metab Dispos; 2006 May; 34(5):765-74. PubMed ID: 16467136
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys.
Tan EY; Hartmann G; Chen Q; Pereira A; Bradley S; Doss G; Zhang AS; Ho JZ; Braun MP; Dean DC; Tang W; Kumar S
Drug Metab Dispos; 2010 Mar; 38(3):459-73. PubMed ID: 20016052
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic/pharmacodynamic modeling of renin biomarkers in subjects treated with the renin inhibitor aliskiren.
Hong Y; Dingemanse J; Mager DE
Clin Pharmacol Ther; 2008 Jul; 84(1):136-43. PubMed ID: 18288088
[TBL] [Abstract][Full Text] [Related]
20. SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren.
Tapaninen T; Karonen T; Backman JT; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2013 Jan; 23(1):19-24. PubMed ID: 23151832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
